• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol Structural Variations and Expression Profiles of the SARS-CoV-2 Host Invasion Genes in Lung Cancer

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Jun 3.
doi: 10.1002/jmv.26107. Online ahead of print.
Structural Variations and Expression Profiles of the SARS-CoV-2 Host Invasion Genes in Lung Cancer


Rahşan Ilikci Sagkan[SUP] 1 [/SUP], Dilara Fatma Akin-Bali[SUP] 2 [/SUP]



Affiliations

Abstract

Recent days have seen growing evidence of cancer's susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of the effect of genomic differences on the virus' entrance genes in lung cancer. Genetic confirmation of the hypotheses regarding gene expression and mutation pattern of target genes, including Angiotensin Converting Enzyme-2 (ACE2), Transmembrane Serine Protease 2 (TMPRSS2), Basigin (CD147/BSG) and Paired Basic Amino Acid Cleaving Enzyme (FURIN/PCSK3), as well as correlation analysis, were evaluated in lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) using in silico analysis. Not only were gene expression and mutation patterns detected, but also there was a correlation and survival analysis between ACE2 and other target genes expression levels. The total genetic anomaly carrying rate of target genes, including ACE2, TMPRSS2, CD147/BSG and FURIN/PCSK3, was determined as 8.1% and 21 mutations detected, with 7 of these mutations having pathogenic features. p.H34N on the RBD binding residues for SARS-CoV-2 was determined in our LUAD patient group. According to gene expression analysis results in LUAD and LUSC patient groups, while the TMPRSS2 level was statistically significantly decreased in the LUSC patient group compared to healthy control, the ACE2 level was determined to be high in LUAD and LUSC. There were no meaningful differences in expression of CD147 and FURIN genes. The challenge for the today is building the assessment of genomic susceptibility to COVID-19 in lung cancer, requiring detailed experimental laboratory studies, in addition to in silico analyses, as a way of assessing the mechanism of novel virus invasion that can be used in the development of effective SARS-CoV-2 therapy. This article is protected by copyright. All rights reserved.

Keywords: ACE2; CD147; Covid-19; FURIN; Severe acute respiratory syndrome coronavirus 2; TMPRSS2; lung cancer.
 
Back
Top Bottom